LI.FI has introduced its Smart Execution suite, integrating tools that enhance crypto transactions by screening same-chain routes, recommending slippage settings, and simplifying deposits. The suite includes Quote Simulation, which tests routes against current blockchain conditions to reduce failed transactions; Smart Slippage, which suggests optimal slippage tolerance for swaps; and Smart Deposit Addresses, which assign unique addresses to transactions for easier fund transfers without extra approvals. These combined features aim to make crypto swaps more reliable and user-friendly, building on LI.FI's previous individual tool releases.
LI.FI's Smart Execution suite launches as a new toolset for crypto transactions. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 20, 2026 02:41 WIB: out of 50 major cryptocurrencies, 43 rose and 6 fell today. Notable movers include UNI (Uniswap) at Rp129.875 with a 4.40% increase and a typical hold time of 65 days, EGLD (MultiversX) at Rp64.686 up 4.34% with an 86-day hold, and SUSHI (SushiSwap) at Rp3.878 rising 4.29% with a 102-day hold time. Pluang order activity shows UNI favored by buyers at 66%, EGLD at 57%, and SUSHI at 45%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
